Israel aims to test BriLife vaccine candidate as booster dose


January 28, 2022

(JNS) — Israel is preparing to test its novel coronavirus vaccine candidate, BriLife, as a booster dose, NRx Pharmaceuticals reported this week.

The American company signed an agreement with the Defense Ministry in July to help fast-track the vaccine, developed by the Israel Institute for Biological Research. NRx, which is traded on Nasdaq, was given exclusive worldwide development, manufacturing and marketing rights.

NRx met with IIBR experts last week to review data and research related to BriLife’s efficacy against the Omicron variant of the SARS-CoV-2 virus, professor Jonathan Ja...

For access to this article please sign in or subscribe.


Reader Comments(0)


Powered by ROAR Online Publication Software from Lions Light Corporation
© Copyright 2023